AnaptysBio Inc. (ANAB) Share Price Today, Stock Analysis, Annual Report | Value Research AnaptysBio Inc. (ANAB) - Get live share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial report.
  • Price Change
  • Market Capitalisation market-capitalisation-info $496 Mln

  • 12 Month Earnings monthly-earning $-137 Mln
  • Price to Earnings price-to-earning --

AnaptysBio Inc. (ANAB) Share Price

$17.96

As on 29-Sep-2023 16:00 EDT

up-down-arrow $-0.04-0.22%

  • Prev Close info

    $18.00

  • Day's Openinfo

    $18.09

  • Today's Highinfo

    $18.09

  • Today's Lowinfo

    $17.43

  • Today's Volumeinfo

    182,004

Please wait...

AnaptysBio Inc. (ANAB) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
AnaptysBio (ANAB)
-42.05 -11.83 -13.70 -31.29 8.22 -29.03 --
S&P BSE Sensex
8.20 1.28 2.99 16.31 20.12 12.69 12.81
#
-- -- -- -- -- -- --
As on 29-Sep-2023  |  #As on
2022
2021
2020
2019
2018
AnaptysBio (ANAB)
-10.82 61.63 32.31 -74.53 -36.51
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

AnaptysBio Inc. (ANAB) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of AnaptysBio Inc. (ANAB)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Interim Pres & CEO and Director

        Mr. Daniel R. Faga

        COO & Gen. Counsel

        Mr. Eric J. Loumeau

        Headquarters

        San Diego, CA

        FAQs for AnaptysBio Inc. (ANAB)

        The total asset value of AnaptysBio Inc. (ANAB) stood at $ 588 Mln as on 31-Mar-23

        The share price of AnaptysBio Inc. (ANAB) is $17.960000 (NASDAQ) as of 29-Sep-2023 16:00 EDT. AnaptysBio Inc. (ANAB) has given a return of 8.22% in the last 3 years.

        AnaptysBio Inc. (ANAB) has a market capitalisation of $ 496 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

        The P/B ratio of AnaptysBio Inc. (ANAB) is 3.00 times as on 02-Jun-2023, a 0.18% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of AnaptysBio Inc. (ANAB) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the AnaptysBio Inc. (ANAB) and enter the required number of quantities and click on buy to purchase the shares of AnaptysBio Inc. (ANAB).

        AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

        The CEO & director of Mr. Daniel R. Faga. is AnaptysBio Inc. (ANAB), and CFO & Sr. VP is Mr. Eric J. Loumeau.

        The promoters of AnaptysBio Inc. (ANAB) have pledged 0% of the total equity as on Mar-23.

        AnaptysBio Inc. (ANAB) Ratios
        Return on equity(%)
        -63.81
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of AnaptysBio Inc. (ANAB) was $-137 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $495.84 Mln
        • Revenue (TTM)revenue-information $10.69 Mln
        • Earnings (TTM) earning-information $-136.72 Mln
        • Cash date-information $431.15 Mln
        • Total Debt info $19.06 Mln
        • Insider's Holding 0.31%
        • Liquidity liquidity High
        • 52 Week range week-range $16.52 - 32.44
        • Shares outstanding share-outstanding 26,487,200
        • 10 Years Aggregate:

          CFO: $-281.02 Mln

          EBITDA: $-374.81 Mln

          Net Profit: $-404.22 Mln

        About The Company

        • IPO Date 26-Jan-2017
        • Interim Pres & CEO and Director Mr. Daniel R. Faga
        • COO & Gen. Counsel Mr. Eric J. Loumeau
        • Listing key-listing NASDAQ: ANAB
        • Country United States
        • Headquarters headquarters San Diego, CA
        • Website website https://www.anaptysbio.com
        • Business

          AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of...  generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon